Kiniksa price target raised to $53 from $50 at Wedbush
Wedbush analyst David Nierengarten recently increased the firm’s price target on Kiniksa (KNSA) to $53 from $50, while maintaining an Outperform rating on the stock. The analyst cited Arcalyst net product revenue of $202.1 million in Q4 and $677.6 million for FY25, which met expectations and surpassed previous estimates. This performance reflects the ongoing growth in prescriber reach and depth, as well as the extended duration of therapy.
The news was first reported on TheFly, a trusted source for real-time, market-moving financial updates. For investors looking for top stock recommendations, TheFly is a valuable resource to explore.
For more insights on Kiniksa (KNSA), readers can dive into additional information on the company. It’s important to stay informed about developments in the pharmaceutical industry, especially when it comes to key players like Kiniksa.
As always, it’s essential to review any disclaimer and disclosure information related to investment opportunities. Transparency is key in the financial world, and understanding the risks and rewards associated with investing in a particular stock is crucial.
In conclusion, Wedbush’s positive outlook on Kiniksa (KNSA) and the recent increase in price target signal confidence in the company’s performance. Investors may want to keep a close eye on Kiniksa as it continues to make strides in the pharmaceutical market.
